Ocugen, In_老虎社区_美港股上老虎

chansin
2021-11-05

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that it has submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of Ocugen’s COVID-19 vaccine candidate BBV152, known as COVAXIN™ outside of the U.S., for pediatric use. The vaccine candidate was developed by the company’s partner, Bharat Biotech, and was studied in an immuno-bridging clinical trial conducted in India with children 2-18 years of age

@me168：

$Histogenics(OCGN)$https://youtu.be/TUMlkkCBPfY start listening from 2h18min mark. Let Dr Fauci answer our doubts

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":846719577,"tweetId":"846719577","gmtCreate":1636113317438,"gmtModify":1636113800478,"author":{"id":3571713327164339,"idStr":"3571713327164339","authorId":3571713327164339,"authorIdStr":"3571713327164339","name":"chansin","avatar":"https://static.tigerbbs.com/a0eb88e173f11f1b4d84ab4e7bf4648b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":14,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that it has submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of Ocugen’s COVID-19 vaccine candidate BBV152, known as COVAXIN™ outside of the U.S., for pediatric use. The vaccine candidate was developed by the company’s partner, Bharat Biotech, and was studied in an immuno-bridging clinical trial conducted in India with children 2-18 years of age</body></html>","htmlText":"<html><head></head><body>Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that it has submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of Ocugen’s COVID-19 vaccine candidate BBV152, known as COVAXIN™ outside of the U.S., for pediatric use. The vaccine candidate was developed by the company’s partner, Bharat Biotech, and was studied in an immuno-bridging clinical trial conducted in India with children 2-18 years of age</body></html>","text":"Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that it has submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of Ocugen’s COVID-19 vaccine candidate BBV152, known as COVAXIN™ outside of the U.S., for pediatric use. The vaccine candidate was developed by the company’s partner, Bharat Biotech, and was studied in an immuno-bridging clinical trial conducted in India with children 2-18 years of age","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/846719577","repostId":846702884,"repostType":1,"repost":{"magic":2,"id":846702884,"tweetId":"846702884","gmtCreate":1636110815594,"gmtModify":1636111261841,"author":{"id":3575026186751523,"idStr":"3575026186751523","authorId":3575026186751523,"authorIdStr":"3575026186751523","name":"me168","avatar":"https://static.tigerbbs.com/842bb1acf5012d1cb565b53b554785d0","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":31,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://static.tigerbbs.com/5d6c69b4402ed66acdc7b20610d0feca","width":"1080","height":"2400"}],"coverImages":[{"img":"https://static.tigerbbs.com/5d6c69b4402ed66acdc7b20610d0feca","width":"1080","height":"2400"}],"extraTitle":"","html":"<html><head></head><body><a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>https://youtu.be/TUMlkkCBPfY start listening from 2h18min mark. Let Dr Fauci answer our doubts&nbsp;<img src=\"https://static.tigerbbs.com/5d6c69b4402ed66acdc7b20610d0feca\" tg-width=\"1080\" tg-height=\"2400\"></body></html>","htmlText":"<html><head></head><body><a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>https://youtu.be/TUMlkkCBPfY start listening from 2h18min mark. Let Dr Fauci answer our doubts&nbsp;<img src=\"https://static.tigerbbs.com/5d6c69b4402ed66acdc7b20610d0feca\" tg-width=\"1080\" tg-height=\"2400\"></body></html>","text":"$Histogenics(OCGN)$https://youtu.be/TUMlkkCBPfY start listening from 2h18min mark. Let Dr Fauci answer our doubts","highlighted":1,"essential":1,"paper":1,"link":"https://laohu8.com/post/846702884","repostId":0,"isVote":1,"tweetType":1,"commentLimit":10,"symbols":["OCGN"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":102,"xxTargetLangEnum":"ZH_CN"},"isVote":1,"tweetType":1,"viewCount":922,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["CRCT","OCGN","TERN"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":484,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}